Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Mycosis Fungoides 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, B-Cell 1Leukemia, Myeloid, Acute 1Immunoblastic Lymphadenopathy 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Renal Cell 1

Interventions

Nivolumab 28pembrolizumab 24cabozantinib 22Ipilimumab 19Specimen Handling 14Magnetic Resonance Spectroscopy 13Axitinib 12lenvatinib 10Radiosurgery 9belzutifan 8CTLA-4 Antigen 7Biopsy 7atezolizumab 6cemiplimab 5Radiotherapy 5Bevacizumab 5toripalimab 4Everolimus 4Blood Specimen Collection 4avelumab 3aldesleukin 3X-Rays 3Sunitinib 3Standard of Care 3Paclitaxel 3zimberelimab 2trastuzumab deruxtecan 2tivozanib 2spartalizumab 2pazopanib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Carcinoma, Renal Cell × sodium-iodide symporter × Clear all
NCT07510334 2026-06-05

VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Mayo Clinic

Phase 2 Recruiting
18 enrolled
Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡